中药龟耳仙角减轻晚期肺癌患者化疗后骨髓抑制

Yan Chen , Hongjie Chen , Yue Li , Zexiong Chen , Yingzi Wu , Eileen McGowan , Xianqin Qu , Yiguang Lin , Baoguo Sun
{"title":"中药龟耳仙角减轻晚期肺癌患者化疗后骨髓抑制","authors":"Yan Chen ,&nbsp;Hongjie Chen ,&nbsp;Yue Li ,&nbsp;Zexiong Chen ,&nbsp;Yingzi Wu ,&nbsp;Eileen McGowan ,&nbsp;Xianqin Qu ,&nbsp;Yiguang Lin ,&nbsp;Baoguo Sun","doi":"10.1016/j.tmsr.2020.05.001","DOIUrl":null,"url":null,"abstract":"<div><p>In recent decades, a classic recipe in traditional Chinese medicine, Guilu erxian jiao (GEJ), has been used in the prevention and treatment of myelosuppression following cancer chemotherapy. However, the safety and efficacy of GEJ has not been studied. In the present study, we investigated the safety and efficacy of GEJ in the management of myelosuppression in a cohort of advanced lung adenocarcinoma patients who received 4 cycles of chemotherapy. Treatment with GEJ was compared to the conventional treatment with pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF). The GEJ treatment group (38 patients) was orally administered GEJ whilst the control group (25 patients) were treated with PEG-rhG-CSF during the 4 cycles of chemotherapy. We found that GEJ was as safe as the recommended treatment, PEG-rhG-CSF. GEJ patients recovered from suppressed bone marrow in a much steadier approach, compared with the highly fluctuating changes observed in PEG-rhG-CSF treatment. Our data suggests that GEJ may be a better alternative to manage cancer chemotherapy-induced myelosuppression.</p></div>","PeriodicalId":23223,"journal":{"name":"Translational Metabolic Syndrome Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tmsr.2020.05.001","citationCount":"2","resultStr":"{\"title\":\"Chinese herbal medicine Guilu erxian jiao attenuates bone marrow suppression following chemotherapy in patients with advanced lung cancer\",\"authors\":\"Yan Chen ,&nbsp;Hongjie Chen ,&nbsp;Yue Li ,&nbsp;Zexiong Chen ,&nbsp;Yingzi Wu ,&nbsp;Eileen McGowan ,&nbsp;Xianqin Qu ,&nbsp;Yiguang Lin ,&nbsp;Baoguo Sun\",\"doi\":\"10.1016/j.tmsr.2020.05.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>In recent decades, a classic recipe in traditional Chinese medicine, Guilu erxian jiao (GEJ), has been used in the prevention and treatment of myelosuppression following cancer chemotherapy. However, the safety and efficacy of GEJ has not been studied. In the present study, we investigated the safety and efficacy of GEJ in the management of myelosuppression in a cohort of advanced lung adenocarcinoma patients who received 4 cycles of chemotherapy. Treatment with GEJ was compared to the conventional treatment with pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF). The GEJ treatment group (38 patients) was orally administered GEJ whilst the control group (25 patients) were treated with PEG-rhG-CSF during the 4 cycles of chemotherapy. We found that GEJ was as safe as the recommended treatment, PEG-rhG-CSF. GEJ patients recovered from suppressed bone marrow in a much steadier approach, compared with the highly fluctuating changes observed in PEG-rhG-CSF treatment. Our data suggests that GEJ may be a better alternative to manage cancer chemotherapy-induced myelosuppression.</p></div>\",\"PeriodicalId\":23223,\"journal\":{\"name\":\"Translational Metabolic Syndrome Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.tmsr.2020.05.001\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational Metabolic Syndrome Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2588930320300062\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Metabolic Syndrome Research","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2588930320300062","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

近几十年来,中药中的经典配方——龟耳仙胶(GEJ)一直被用于预防和治疗癌症化疗后的骨髓抑制。然而,GEJ的安全性和有效性尚未得到研究。在本研究中,我们研究了GEJ治疗接受4个化疗周期的晚期肺腺癌患者骨髓抑制的安全性和有效性。将GEJ治疗与聚乙二醇化重组人粒细胞集落刺激因子(PEG-rhG-CSF)的常规治疗进行比较。GEJ治疗组(38例)采用口服GEJ治疗,对照组(25例)采用PEG-rhG-CSF治疗,共4个化疗周期。我们发现GEJ与推荐治疗PEG-rhG-CSF一样安全。与PEG-rhG-CSF治疗中观察到的高度波动变化相比,GEJ患者从抑制骨髓中恢复的方式更加稳定。我们的数据表明,GEJ可能是治疗癌症化疗诱导的骨髓抑制的更好选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Chinese herbal medicine Guilu erxian jiao attenuates bone marrow suppression following chemotherapy in patients with advanced lung cancer

In recent decades, a classic recipe in traditional Chinese medicine, Guilu erxian jiao (GEJ), has been used in the prevention and treatment of myelosuppression following cancer chemotherapy. However, the safety and efficacy of GEJ has not been studied. In the present study, we investigated the safety and efficacy of GEJ in the management of myelosuppression in a cohort of advanced lung adenocarcinoma patients who received 4 cycles of chemotherapy. Treatment with GEJ was compared to the conventional treatment with pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF). The GEJ treatment group (38 patients) was orally administered GEJ whilst the control group (25 patients) were treated with PEG-rhG-CSF during the 4 cycles of chemotherapy. We found that GEJ was as safe as the recommended treatment, PEG-rhG-CSF. GEJ patients recovered from suppressed bone marrow in a much steadier approach, compared with the highly fluctuating changes observed in PEG-rhG-CSF treatment. Our data suggests that GEJ may be a better alternative to manage cancer chemotherapy-induced myelosuppression.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Review of the methods to measure non-adherence with a focus on chemical adherence testing Glycome assessment in patients with respiratory diseases The role of IgG N-galactosylation in spondyloarthritis Semaglutide is precipitating a revolution in obesity care The efficacy of dairy products fortified with nano-encapsulated vitamin D3 on physical and mental aspects of the health in obese subjects; the protocol of the SUVINA trial
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1